Last reviewed · How we verify
Ticagrelor + ASA + Bivalirudin
This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events.
This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Prevention of stent thrombosis and recurrent ischemic events.
At a glance
| Generic name | Ticagrelor + ASA + Bivalirudin |
|---|---|
| Also known as | Brilinta (ticagrelor, Aspirin (ASA), Angiomax (bivalirudin) |
| Sponsor | Juan J Badimon |
| Drug class | Antiplatelet agent + anticoagulant combination |
| Target | P2Y12 receptor, COX-1, thrombin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 receptor antagonist that blocks ADP-mediated platelet activation, while aspirin irreversibly inhibits cyclooxygenase-1 to reduce thromboxane A2 production. Bivalirudin is a direct thrombin inhibitor that prevents fibrin formation and thrombus propagation. Together, this triple antithrombotic regimen targets multiple pathways of coagulation and platelet function to reduce ischemic cardiovascular events.
Approved indications
- Acute coronary syndrome with percutaneous coronary intervention
- Prevention of stent thrombosis and recurrent ischemic events
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
- Hypotension
Key clinical trials
- Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers (PHASE4)
- Antithrombotic Effects of Ticagrelor Versus Clopidogrel (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor + ASA + Bivalirudin CI brief — competitive landscape report
- Ticagrelor + ASA + Bivalirudin updates RSS · CI watch RSS
- Juan J Badimon portfolio CI